Quick answer: An estimated 20 million Americans have thyroid disease, with 60% undiagnosed — and of those diagnosed, the majority are treated with levothyroxine alone (T4 only), despite evidence that 20% of patients on levothyroxine have persistent hypothyroid symptoms because they cannot efficiently convert T4 to the active T3 hormone (Gullo 2011, Journal of Clinical Endocrinology & Metabolism). Hashimoto’s thyroiditis — the autoimmune root cause of up to 90% of hypothyroidism in developed countries — is almost never addressed at its immune root in conventional medicine, meaning the autoimmune destruction continues regardless of how well TSH is normalized with hormone replacement.
The Thyroid Hormone Cascade: T4, T3, Reverse T3, and Why TSH Alone Is Insufficient
The thyroid gland produces primarily T4 (thyroxine — 80% of thyroid hormone output) and some T3 (triiodothyronine — the biologically active hormone — 20% direct production). T4 is essentially a prohormone that must be converted to T3 by deiodinase enzymes (primarily type 2 deiodinase in peripheral tissues) to exert biological activity. T3 is 3–5× more biologically potent than T4 and is responsible for virtually all thyroid hormone effects at the cellular level: metabolic rate, mitochondrial biogenesis, thermogenesis, brain development, protein synthesis, gut motility, and cardiac function. TSH (thyroid-stimulating hormone) from the pituitary provides a feedback signal for circulating thyroid hormone levels — but TSH is a measure of pituitary sensing of T4, not of intracellular T3 activity where all thyroid effects occur.
The critical clinical problem: many patients have “normal” TSH but low free T3 — and it is free T3, not TSH, that correlates with hypothyroid symptoms, metabolic rate, cognitive function, and quality of life outcomes. The T4-to-T3 conversion step (via type 1 and type 2 deiodinase) is impaired by multiple modifiable factors: Selenium deficiency (selenoproteins including type I and type II iodothyronine deiodinase are selenium-dependent enzymes — selenium deficiency impairs T4-to-T3 conversion and increases reverse T3 production); Chronic inflammation (IL-6, TNF-α, and IL-1β all suppress deiodinase activity — explaining why chronic illness and autoimmune disease produce “sick euthyroid syndrome” with low T3 despite normal TSH); Chronic stress and elevated cortisol (cortisol suppresses TRH secretion, reduces T3 receptor sensitivity, and promotes reverse T3 production); Iron deficiency (thyroid peroxidase — the enzyme synthesizing thyroid hormones — is iron-dependent; even subclinical iron deficiency impairs thyroid hormone synthesis); Insulin resistance (impairs cellular T3 uptake); and Environmental toxins (PCBs, mercury, bromides, and fluoride compete with iodine or directly impair thyroid hormone synthesis).
Reverse T3 (rT3) is a non-biologically active isomer of T3 produced by type 3 deiodinase — the body’s mechanism for reducing metabolic rate during illness, caloric restriction, and high stress. Elevated rT3 competes with T3 for thyroid hormone receptors (both use the same receptor binding site), effectively blocking T3 activity even when free T3 levels appear adequate. Chronic stress, caloric restriction, high-cortisol states, liver dysfunction, and selenium deficiency all preferentially shunt T4 toward rT3 instead of T3. The free T3:rT3 ratio (optimal >20) is more clinically informative than either measurement alone. Addressing elevated rT3 requires addressing its root causes rather than simply changing thyroid medication — cortisol normalization (DUTCH testing), selenium repletion, treating underlying inflammation, and iron repletion are the foundational interventions.
Hashimoto’s Thyroiditis: An Autoimmune Disease That Can Be Addressed at Its Root
Hashimoto’s thyroiditis is the most common autoimmune disease in the United States — affecting approximately 10 million Americans, predominantly women (7–10:1 female-to-male ratio). It is characterized by lymphocytic infiltration of the thyroid gland, elevated anti-thyroid peroxidase (anti-TPO) antibodies, and progressive destruction of thyroid tissue over years to decades. Conventional medicine treats Hashimoto’s exclusively by replacing the hormones lost as the thyroid is destroyed — a reasonable intervention that addresses the downstream hormonal deficiency but does nothing to slow the autoimmune attack on the thyroid tissue itself.
The functional medicine approach to Hashimoto’s identifies the known modifiable triggers and applies targeted interventions: Gluten and molecular mimicry — the gliadin protein in gluten shares molecular homology with thyroid tissue proteins; anti-gliadin antibodies can cross-react with thyroid antigens, amplifying thyroid-directed autoimmunity in susceptible individuals. Sategna-Guidetti 2001 demonstrated that 3–5 years on a strict gluten-free diet normalized thyroid antibodies and restored thyroid function in celiac disease patients with Hashimoto’s. Multiple clinical studies and extensive case series demonstrate anti-TPO antibody reductions of 20–50% with strict gluten elimination in antibody-positive Hashimoto’s patients. Celiac disease co-occurs with Hashimoto’s at 3–5× the expected rate — all Hashimoto’s patients warrant celiac serology (tTG-IgA, DGP-IgG) and potentially HLA-DQ2/DQ8 genotyping. Selenium supplementation has the strongest RCT evidence in Hashimoto’s. Gärtner 2002 (Journal of Clinical Endocrinology & Metabolism) found selenium 200 mcg/day for 3 months reduced anti-TPO antibodies by 36% versus 10% in placebo in 70 Hashimoto’s patients. A 2017 meta-analysis of 9 RCTs confirmed selenium significantly reduces anti-TPO and anti-Tg antibodies while reducing ultrasound echogenicity (a marker of thyroid inflammation). The mechanism involves the selenoprotein thioredoxin reductase (TrxR) neutralizing hydrogen peroxide generated during thyroid hormone synthesis — oxidative stress is central to Hashimoto’s pathogenesis, and selenium deficiency allows this oxidative damage to amplify the autoimmune cascade.
Iodine — the Hashimoto’s controversy: Iodine is required for thyroid hormone synthesis, but excessive iodine in Hashimoto’s patients can paradoxically worsen autoimmunity through the Wolff-Chaikoff effect and by generating additional hydrogen peroxide beyond the buffering capacity of glutathione and selenoproteins. Excessive iodine supplementation in selenium-deficient Hashimoto’s patients consistently worsens anti-TPO titers in clinical studies (Teng 2006, NEJM Chinese epidemic study). The functional approach: ensure selenium adequacy BEFORE iodine supplementation; use modest iodine doses (150–300 mcg/day — not the megadose 12.5 mg protocols that are potentially dangerous in autoimmune thyroid disease); monitor anti-TPO antibodies with any iodine supplementation. Vitamin D deficiency is 2–4× more prevalent in Hashimoto’s than in healthy controls across multiple studies — and vitamin D directly suppresses Th17 differentiation (the autoimmune driver in Hashimoto’s) and promotes Treg expansion. Wang 2015 meta-analysis confirmed significant inverse correlation between vitamin D status and both anti-TPO antibody titers and TSH levels in Hashimoto’s. Target 60–80 ng/mL. Low-dose naltrexone (LDN) 1.5–4.5 mg modulates TLR4 on thyroid immune cells and is increasingly used in autoimmune thyroid disease — case series from Bihari’s original work and subsequent clinical experience demonstrate anti-TPO reduction and improved thyroid function with LDN in Hashimoto’s.
Comprehensive Thyroid Testing: What You Should Be Getting
The complete functional thyroid panel goes far beyond what most physicians order. Essential tests: TSH (with functional target 0.5–2.0 mU/L — not the laboratory “normal” range of 0.5–4.5, which was set based on population averages including symptomatic hypothyroid individuals); Free T4 (functional target mid-to-upper normal range: 1.1–1.8 ng/dL); Free T3 (the most important thyroid metric for symptom correlation — functional target upper third of normal range: 3.5–4.5 pg/mL); Reverse T3 (functional target <15 ng/dL; T3:rT3 ratio >20); Anti-TPO antibodies (elevated in Hashimoto’s; goal is reduction toward normal with treatment — target <35 IU/mL); Anti-thyroglobulin antibodies (anti-Tg — present in 20–30% of Hashimoto’s cases without anti-TPO elevation); TgAb — combined with anti-TPO provides higher sensitivity for detecting autoimmune thyroid disease than anti-TPO alone. Thyroid ultrasound — identifies nodules, heterogeneity (characteristic of Hashimoto’s), goiter, and calcifications; essential for any patient with palpable thyroid abnormality or antibody positivity without nodule history. Selenium (serum or RBC) — guides supplementation decisions in Hashimoto’s. Iron panel with ferritin — ferritin below 40–50 ng/mL impairs thyroid hormone synthesis (thyroid peroxidase is iron-dependent) and is extremely common in premenopausal women with Hashimoto’s. Vitamin D (25-OH-D3). Morning cortisol — severe adrenal insufficiency should be excluded before initiating thyroid hormone replacement (thyroid hormone increases cortisol clearance, potentially precipitating adrenal crisis in undiagnosed Addison’s disease).
Thyroid Medication Options: T4, T3, and Combination Therapy
Levothyroxine (synthetic T4 — Synthroid, Tirosint) is the standard-of-care first-line treatment and is appropriate for patients who efficiently convert T4 to T3. Tirosint (liquid gel cap formulation) has superior absorption in patients with gut malabsorption (SIBO, celiac disease, hypochlorhydria) — bioavailability 20–30% higher than tablet formulations. Liothyronine (synthetic T3) added to levothyroxine addresses impaired T4-to-T3 conversion — a 1999 NEJM study (Bunevicius) demonstrated that T4+T3 combination improved cognitive function, quality of life, mood, and physical symptoms in hypothyroid patients significantly better than T4 alone. Gullo 2011 found 49% of hypothyroid patients on T4 preferred T3-containing therapy in a crossover study. The conventional endocrinology resistance to T3 (based on concerns about cardiac effects at high doses and T3’s shorter half-life causing fluctuating levels) is addressed by using slow-release compounded T3 or by the alternative: Natural desiccated thyroid (NDT — Armour Thyroid, NP Thyroid, Nature-Throid) — derived from porcine thyroid glands, containing both T4 and T3 in their naturally occurring ratio (approximately 4:1 T4:T3), plus T2, T1, calcitonin, and thyroglobulin. Many patients with “normal TSH” on levothyroxine who remain symptomatic report significant improvement when switched to NDT. NDT is particularly appropriate for patients with impaired T4-to-T3 conversion and elevated reverse T3.
Subclinical Hypothyroidism: The Functional Medicine Approach
Subclinical hypothyroidism (SCH) is defined as elevated TSH (4.5–10 mU/L) with normal free T4. Conventional endocrinology treats SCH only when TSH exceeds 10 mU/L or the patient has specific comorbidities — leaving millions with TSH 4.5–9.9 without treatment despite symptoms. Functional medicine applies a symptom-first approach: SCH patients with fatigue, weight gain, cognitive symptoms, depression, hair loss, cold intolerance, constipation, or elevated anti-TPO antibodies warrant treatment trial regardless of the specific TSH number, given the established associations between even mildly elevated TSH and increased cardiovascular risk (Cappola 2006, JAMA — TSH above 4.5 was associated with significantly increased cardiovascular mortality), impaired cognitive function (Jorde 2006 — significant improvement in cognitive performance with T4 treatment in SCH), infertility (SCH doubles miscarriage risk; consensus guidelines recommend treatment in pregnancy or pre-conception with TSH >2.5 mU/L), and depression (SCH correlates with higher PHQ-9 depression scores — improved significantly with levothyroxine in multiple RCTs). The aggressive functional target TSH 0.5–2.0 mU/L reflects the true physiological normal range that correlates with optimal quality of life outcomes across studies.
Frequently Asked Questions
Why do I still have hypothyroid symptoms if my TSH is normal?
TSH alone is an inadequate thyroid marker for symptom correlation. Free T3 — the biologically active hormone — may be low even with normal TSH if: T4-to-T3 conversion is impaired (by selenium deficiency, chronic inflammation, chronic stress, iron deficiency, or insulin resistance); reverse T3 is elevated (competing with T3 for receptors); or TSH is “normal” but at the high end of range (above 2.0 mU/L) where many patients experience hypothyroid symptoms. Complete thyroid panel including free T3, reverse T3, and thyroid antibodies identifies the specific mechanism — and can be directly treated.
Can Hashimoto’s thyroiditis be reversed?
Hashimoto’s cannot typically be “reversed” in the sense of eliminating existing thyroid damage. However, the autoimmune attack can be dramatically slowed and anti-TPO antibodies can be significantly reduced. Selenium 200 mcg/day reduced anti-TPO antibodies by 36% in RCT (Gärtner 2002). Strict gluten elimination reduced antibodies 20-50% in multiple studies and normalized thyroid function in celiac-Hashimoto’s patients. Vitamin D optimization to 60-80 ng/mL, LDN, and addressing other autoimmune triggers (gut permeability, infections) collectively reduce the autoimmune activity — slowing the progressive destruction that would otherwise require ever-increasing thyroid hormone replacement.
What is the difference between T4 and T3 thyroid medication?
T4 (levothyroxine — Synthroid) is a prohormone that must be converted to active T3 in peripheral tissues. T3 (liothyronine) is the biologically active hormone directly usable by cells. Approximately 20% of patients on T4 alone have persistent hypothyroid symptoms despite normalized TSH because they cannot efficiently convert T4 to T3. A 1999 NEJM study found T4+T3 combination significantly improved cognitive function, mood, and physical symptoms versus T4 alone. Natural desiccated thyroid (Armour) contains both T4 and T3 in the naturally occurring 4:1 ratio and is preferred by many functional medicine practitioners for poor T4-converters.
Is Hashimoto’s disease caused by gluten?
Gluten is not the sole cause, but it is a significant trigger in genetically susceptible individuals. Gliadin (the gluten protein) shares molecular homology with thyroid tissue antigens — anti-gliadin antibodies can cross-react with thyroid proteins, amplifying the autoimmune attack. Celiac disease co-occurs with Hashimoto’s at 3-5x the expected rate. Strict gluten elimination for 3-5 years normalized thyroid antibodies in celiac-Hashimoto’s patients in Sategna-Guidetti 2001. All Hashimoto’s patients should be tested for celiac disease (tTG-IgA) and undergo a 3-6 month gluten elimination trial to assess antibody response.
Optimal thyroid function is foundational to energy, metabolism, brain health, cardiovascular function, fertility, and immune regulation. At The Private Practice, we provide comprehensive thyroid evaluation including free T3, reverse T3, anti-TPO, anti-Tg, thyroid ultrasound when indicated, and precision treatment addressing both the hormonal deficiency and the autoimmune root cause of Hashimoto’s thyroiditis. Call us at (810) 206-1402 to schedule your thyroid consultation.